$ARTL surged 92% on buy rating from Ladenburg analyst
Artelo Biosciences surged 92% on buy initiation from Ladenburg
Shares of
ARTL Artelo Biosciences surged on friday after Ladenburg analyst Michael Higgins initiated the company with a buy rating.
They give the biopharma a $7 price target. It also represents a potential 329% upside over the stock’s closing price on Thursday.
Ladenburg analyst cites Artelo's focus on candidates targeting the endocannabinoid system.
Artelo Biosciences is a biopharma company focused on developing treatments that improve patients’ lives. That includes developing new therapies. The company’s pipeline includes ART27.13, which is designed to treat cancer patients suffering from anorexia. This treatment is currently undergoing a Phase 1 clinical trial.
seekingalpha.com/news/3661712-artelo-biosciences-surges-92-on-buy-initiation-from-ladenburg
investorplace.com/2021/02/artl-stock-alert-the-big-reason-biopharma-artelo-biosciences-is-rocketing-today/
Shares of
ARTL Artelo Biosciences surged on friday after Ladenburg analyst Michael Higgins initiated the company with a buy rating.They give the biopharma a $7 price target. It also represents a potential 329% upside over the stock’s closing price on Thursday.
Ladenburg analyst cites Artelo's focus on candidates targeting the endocannabinoid system.
Artelo Biosciences is a biopharma company focused on developing treatments that improve patients’ lives. That includes developing new therapies. The company’s pipeline includes ART27.13, which is designed to treat cancer patients suffering from anorexia. This treatment is currently undergoing a Phase 1 clinical trial.
seekingalpha.com/news/3661712-artelo-biosciences-surges-92-on-buy-initiation-from-ladenburg
investorplace.com/2021/02/artl-stock-alert-the-big-reason-biopharma-artelo-biosciences-is-rocketing-today/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.